A first-in-class medication, Journavx targets pain-signaling pathways involving sodium channels.
A first-in-class medication, Journavx targets pain-signaling pathways involving sodium channels.
A compound opioid/NOP receptor agonist demonstrated pain relief with a safety profile comparable to placebo.
A new study uses data from 583,000 group health patients with chronic noncancer pain.
Approximately 21% of adults experienced chronic pain in 2021, with greater prevalence among certain demographics.
A new combination of acetaminophen and ibuprofen will soon hit the market.
Extended physical medicine was 5-9 times as common in claims with multiple providers.
Two new studies highlight marijuana’s analgesic effects.
The potential for low amniotic fluid can cause significant health issues.
A systematic review from the Annals of Internal Medicine evaluates different cannabis formulations.
Artri Ajo King contains undeclared diclofenac, creating safety concerns.
